Table 3 Demographic data of metformin and placebo groups
From: Metformin attenuates symptoms of osteoarthritis: role of genetic diversity of Bcl2 and CXCL16 in OA
Variables | Metformin (N = 44) | Placebo (N = 44) | Total (N = 88) | Pc (< 0.05) |
|---|---|---|---|---|
Sex,n(%) | ||||
 Female | 34 (77.3) | 30 (68.2) | 64 (72.7) | 0.344 |
 Male | 10 (22.7) | 14 (31.8) | 24 (27.3) | |
Age (years) | 49.3 ± 9.3 | 47.2 ± 9.0 | 48.3 ± 9.2 | 0.277 |
BMI (kg/m2) | 29.1 ± 3.1 | 29.0 ± 3.8 | 29.1 ± 3.4 | 0.828 |
Cardiovascular dx,n(%) | 13 (29.5) | 8 (18.2) | 21 (23.9) | 0.494 |
Family history (%) | 30 (63.6) | 32 (72.7) | 62 (70.5) | 0.447 |
K-L grade,n(%) | 16 (36.4) | Â | Â | Â |
 1 |  | 20 (45.5) | 36 (40.9) | 0.229 |
 2 | 21 (47.7) | 22 (50) | 43 (48.9) | |
 3 | 7 (15.9) | 2 (4.5) | 9 (10.2) | |